[Clinical value of combined detection of LDH, TPS, CEA and beta2-MG in patients with non- Hodgkin's lymphoma].
OBJECTIVE
To study the clinical value of combined detection of 4 tumor markers, namely lactic dehydrogenate (LDH), tissue polypeptide specific antigen (TPS), carcinoembryonic antigen (CEA) and beta2-microglobulin (beta2-MG) in patients with non-Hodgkin's lymphoma (NHL).


METHODS
The serum level of LDH was determined with automatic biochemical analyzer and TPS, CEA and beta2-MG levels were determined by enzyme-linked immumosorbent assay (ELISA) in 59 patients with NHL and 40 healthy adults.


RESULTS
The levels of the 4 tumor markers were significantly higher in NHL patients than in the healthy control subjects (P<0.05). After chemotherapy, the serum levels of TPS and beta2-MG were significantly lowered in the patients who showed favorable response to the treatment (P<0.05), but the levels of LDH and CEA showed no significant change (P>0.05). The serum levels of LDH, TPS, CEA and beta2-MG in the patients in a stable or progressive phase did had no significant changes after chemotherapy (P>0.05).


CONCLUSIONS
Combined detection of LDH, TPS, CEA and beta2-MG can be helpful to assist diagnosis of NHL and treatment evaluation.
Chen
Wei
W
Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Luo
Rong-cheng
RC
Fan
Wei-wen
WW
Ma
Shu-dong
SD
D000328:Adult; D014408:Biomarkers, Tumor / Q000097:blood; D002272:Carcinoembryonic Antigen / Q000097:blood*; D005260:Female; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000097:blood*; D008228:Lymphoma, Non-Hodgkin / Q000097:blood* / Q000175:diagnosis; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000097:blood*; D011237:Predictive Value of Tests; D001613:beta 2-Microglobulin / Q000097:blood*
D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; D010455:Peptides; D001613:beta 2-Microglobulin; C089984:tissue polypeptide specific antigen; D007770:L-Lactate Dehydrogenase